Catalogo Articoli (Spogli Riviste)

OPAC HELP

Titolo:
Loss of antiretroviral drug susceptibility at low viral load during early virological failure in treatment-experienced patients
Autore:
Parkin, NT; Deeks, SG; Wrin, MT; Yap, J; Grant, RM; Lee, KH; Heeren, D; Hellmann, NS; Petropoulos, CJ;
Indirizzi:
ViroLog Inc, S San Francisco, CA 94080 USA ViroLog Inc S San Francisco CAUSA 94080 c, S San Francisco, CA 94080 USA Univ Calif San Francisco, AIDS Program, San Francisco, CA 94143 USA Univ Calif San Francisco San Francisco CA USA 94143 ancisco, CA 94143 USA Gladstone Inst Virol, San Francisco, CA USA Gladstone Inst Virol San Francisco CA USA t Virol, San Francisco, CA USA
Titolo Testata:
AIDS
fascicolo: 18, volume: 14, anno: 2000,
pagine: 2877 - 2887
SICI:
0269-9370(200012)14:18<2877:LOADSA>2.0.ZU;2-N
Fonte:
ISI
Lingua:
ENG
Soggetto:
IMMUNODEFICIENCY-VIRUS TYPE-1; PROTEASE INHIBITOR THERAPY; PCR ASSAY; RESISTANCE; SAQUINAVIR; RITONAVIR; RNA; QUANTITATION; INFECTION; REGIMEN;
Keywords:
antriretroviral therapy; combination therapy; HIV drug resistance; protease inhibitors; reverse transcriptase inhibitors; reverse transcriptase-polymerase chain reaction; viral load;
Tipo documento:
Article
Natura:
Periodico
Settore Disciplinare:
Life Sciences
Citazioni:
23
Recensione:
Indirizzi per estratti:
Indirizzo: Parkin, NT ViroLog Inc, 270 E Grand Ave, S San Francisco, CA 94080 USA ViroLog Inc 270 E Grand Ave S San Francisco CA USA 94080 80 USA
Citazione:
N.T. Parkin et al., "Loss of antiretroviral drug susceptibility at low viral load during early virological failure in treatment-experienced patients", AIDS, 14(18), 2000, pp. 2877-2887

Abstract

Background: Clinical studies have demonstrated a correlation between the response to second-line antiretroviral therapy and the number of drugs in the regimen to which the virus is susceptible. These studies have largely been performed in patients with viral loads over 1000 copies/ml. Objectives: To examine the evolution of resistance during early virological failure, and the potential role of susceptibility testing in patients with low viral loads (below 1000 copies/ml), in treatment-experienced patients. Methods: Drug susceptibility and genotypes of HIV-1 from indinavir-experienced patients undergoing therapy with nelfinavir, saquinavir, abacavir and either a second nucleoside reverse transcriptase inhibitor (NRTI) or nevirapine were determined. Results: Sixteen subjects were studied. Five of the ten subjects treated with nevirapine, and one of six treated with a second NRTI, achieved and maintained plasma HIV RNA < 500 copies/ml. Virus from the treatment failures lost susceptibility to one or more treatment drugs, including nelfinavir and/or saquinavir, after 4 to 36 weeks of treatment. In six of the ten failures, virus with new reductions in drug susceptibility was detected prior to failure. In five of the six failures who had at least one plasma sample witha viral load between 50 and 1000 copies/ml, reductions in susceptibility to one or more treatment drugs were detected (viral load range: 260 to 630 copies/ml). Conclusions: Drug resistance can be detected at viral loads below 1000 copies/ml which may be predictive of treatment failure. Failure of a second line regimen was typically associated with early evolution of resistance in HIV protease. (C) 2000 Lippincott Williams & Wilkins.

ASDD Area Sistemi Dipartimentali e Documentali, Università di Bologna, Catalogo delle riviste ed altri periodici
Documento generato il 20/10/20 alle ore 00:52:57